Tear Sheet: Rossini Acquisition S.a.r.l.

In the first nine months of 2023, Recordati posted solid 13% top-line growth, or 13.8% like-for-like growth at constant currency. Both business divisions contributed to the growth. In the first nine months of 2023, SPC revenue increased 8.1% from the previous year, supported by robust demand in cough and cold medicines. The rare disease business reported 23.5% sales growth driven by Signifor and Isturisa in the endocrinological therapeutic area, and resilient sales in the metabolic area. As a result, for the year, we expect the company to generate about €2.08 billion in revenue, or 12.3% growth versus 2022, supported by 7%-9% growth from SPC and above 20% growth from the rare diseases business. We anticipate both divisions will expand more

...November 29, 2023 Rossini Acquisition S.a.r.l.'s pharmaceutical operating subsidiary, Recordati SpA, continues its organic growth trajectory, underpinned by specialty and primary care (SPC) and rare diseases. In the first nine months of 2023, Recordati posted solid 13% top-line growth, or 13.8% like-for-like growth at constant currency. Both business divisions contributed to the growth. In the first nine months of 2023, SPC revenue increased 8.1% from the previous year, supported by robust demand in cough and cold medicines. The rare disease business reported 23.5% sales growth driven by Signifor and Isturisa in the endocrinological therapeutic area, and resilient sales in the metabolic area. As a result, for the year, we expect the company to generate about 2.08 billion in revenue, or 12.3% growth versus 2022, supported by 7%-9% growth from SPC and above 20% growth from the rare diseases business. We anticipate both divisions will expand more than 10% in 2024, leading to total revenue...

Full Report